STAT

Opinion: Beyond safety questions, gene editing will force us to deal with a moral quandary

By the time gene-editing services arrive in the marketplace, I hope that people around the world will have developed a more sober attitude towards genetic technology.
A slide from He Jiankui's presentation at the Human Genome Editing Conference in Hong Kong.

After a Chinese scientist announced this week the birth of twin girls whose DNA he had altered many months earlier when they were microscopic, single-cell embryos, condemnation of this previously secret experiment was swift and absolute. Scientists and ethicists from around the world called it “premature” and “irresponsible.”

The majority of this criticism is motivated by major concerns about safety — we simply do not yet know enough about the impact of CRISPR-Cas9, the powerful new gene-editing tool, to use it create children. But there’s a second, equally pressing concern mixed into many of these condemnations: that gene-editing human eggs, sperm, or embryos is morally wrong.

That moral claim may prove more difficult to resolve than the safety questions, because

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks